IXICO PLC PHYOF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.15
- Day Range
- $0.07–0.07
- 52-Week Range
- $0.07–0.15
- Bid/Ask
- $0.00 / $0.77
- Market Cap
- $3.38 Mil
- Volume/Avg
- 200 / 200
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 89
- Website
- https://www.ixico.com
Valuation
|
Metric
|
PHYOF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.27 |
Price/Sales | 0.45 |
Price/Cash Flow | — |
Price/Earnings
PHYOF
Financial Strength
|
Metric
|
PHYOF
|
|---|---|
Quick Ratio | 3.64 |
Current Ratio | 3.64 |
Interest Coverage | −84.48 |
Quick Ratio
PHYOF
Profitability
|
Metric
|
PHYOF
|
|---|---|
Return on Assets (Normalized) | −14.29% |
Return on Equity (Normalized) | −16.42% |
Return on Invested Capital (Normalized) | −16.57% |
Return on Assets
PHYOF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Bgkjsxwlw | Xmh | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kqqxcjdng | Zkrgcn | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vphvppkq | Whdslwb | $118.7 Bil | |||
| Moderna Inc
MRNA
| Xgrzcmdrb | Gbp | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rchkgfy | Zmqpft | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Bhjfsnjpq | Wbmyn | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Wbbwpsmkc | Klpgf | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xhfnsxsw | Ghrhyg | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Xwzxlgnpg | Cvq | $15.0 Bil | |||
| Incyte Corp
INCY
| Bxxdjcpxz | Ftjtg | $13.5 Bil |